Compare FISI & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FISI | CRMD |
|---|---|---|
| Founded | 1817 | 2006 |
| Country | United States | United States |
| Employees | 631 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 677.6M | 618.2M |
| IPO Year | N/A | 2009 |
| Metric | FISI | CRMD |
|---|---|---|
| Price | $34.89 | $7.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $37.00 | $14.83 |
| AVG Volume (30 Days) | 70.1K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | ★ $9.36 | $18.20 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $24.41 | $6.13 |
| 52 Week High | $35.70 | $17.43 |
| Indicator | FISI | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 55.69 |
| Support Level | $33.23 | $6.28 |
| Resistance Level | $35.48 | $8.53 |
| Average True Range (ATR) | 0.79 | 0.41 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 66.34 | 32.45 |
Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.